The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives The trial did not meet one of its ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

Each household can receive up to four free tests from the site COVIDtest.gov. Once ordered, the at-home tests are mailed to ...

Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech. Interim data suggest the vaccine candidates have an acceptable safety and ...

Covid-19 vaccines are available across the United States. Vaccines represent the best protection against sever illness and ...

What it is: An annual influenza vaccine to reduce the ... made by Moderna, Pfizer-BioNTech, and Novavax. The mRNA vaccines—made by Moderna and Pfizer-BioNTech—are approved for use in the ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...